PGX PGX appears to be advancing as expected with two production trial runs completed after initial commissioning of the 5X scale-up. Only one more production run remains. The product could be launched by the end of this year given the Health Canada approvals for CZO's 5X facility. No mention of the strategy for launch or of the CoQ10 initiative and partnering. The 5X facility has been expected to provide materials for potential partners to evaluate. In November CZO also annouunced that it has designed an animal trial protocol to test the product as an immune booster.
News release:
- "We are very pleased with progress made in the development of new products and technologies such as the ongoing Phase 1-2a clinical trial with avenanthramides and the very well-advanced 50L scale-up of the PGX Technology which will enable the development and production of yeast beta glucan as an immune modulator."
- Edmonton Main Facility - PGX Scale-Up 50 Liters Vessel: This project is almost completed. Three trial runs of yeast beta glucan have been performed as part of the last commissioning phase. Given that the Edmonton site license is for natural products, yeast beta glucan produced from this facility will be offered as a nutraceutical. Subject to approval by Health Canada, this product could be launched by end of 2024.
- Natex Facility, Austria - PGX Scale-Up 100 Liters Vessel: The project is on schedule. PGX pressure vessel design is 100% completed. Initial safety and regulatory risk assessment has also been completed. Commissioning is expected to be completed by end of Q3 2024